Navigation Links
TPI Reports Second Quarter Fiscal Year 2013 Financial Results

CHENGDU, China, Feb. 14, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013.

Second Quarter Fiscal Year 2013 Ended December 31, 2012 Financial Highlights:

  • Revenue was $17.6 million compared with $18.2 million in 2Q12 a decrease of 3.3% year over year,
  • Operating income was $2.6 million, compared with $2.1 million in 2Q12, an increase of 23.8% year over year,
  • Net Income was $1.8 million compared with $1.7 million in 2Q12, an increase of 5.9% year over year,
  • Earnings per share of $0.06 per basic share, and $0.06 per diluted share, compared with $0.06 per basic share, or $0.06 per diluted share in 2Q12, 
  • Cash and cash equivalents totaled $25.4 million on December 31, 2012; Operating cash flow for the six months ended December 31, 2012 was $(0.7) million, compared with operating cash flow of $7.9 million for the six months ended December 31, 2011.
  • Comparison of results for the quarters ended December 31, 2012 and 2011:Quarters 
    Ended December 31,20122011(In millions)Sales$


    18.2Cost of sales$


    12.1Gross profit$


    6.1Total operating expenses$


    4.0Operating income$


    2.1Provision for income taxes$


    0.6Net income$


    1.7Sales for the quarter ended December 31, 2012 was $17.6 million, a decrease of 3.3% as compared to $18.2 million for the quarter ended December 31, 2011. The sales decrease was mainly due to continuous generic pricing pressure amid healthcare reform further augmented by restrictive government policies to prioritize the Essential Drug List (EDL) drug sales, which simultaneously reduced the sales of our higher margin generic pharmaceuticals. Our top five product sales are: Gingko mihuan oral liquid (GMOL) for stroke and cardiovascular disorders: $6.5 million; Mycophenolate mofetil capsules (MM) for renal transplant: $2.2 million; Azithromycin tablets (AZI) for infection: $1.0 million; Qingre jiedu oral liquid (QR): $0.8 million and Qianlie Shule capsules (QS) for prostate conditions: $0.38 million. These products totaled $10.9 million in sales, representing 62% of the quarterly revenue. Similar to the first quarter of fiscal 2013, the former two core products Apu Shuangxin (Apu) and Xuelian Chongcao (XLCC) which are not covered by EDL or National Reimbursement List (NRL) lists have not reached the level to be included in the top five products mainly because the healthcare reform regulations favor EDL and NRL drugs. Compared with a year earlier, the total core product sales have risen significantly from $7.5 million for the quarter ended December 31, 2011 mainly due to the significant rise in GMOL sales of 51% year over year from $4.3 million for the quarter ended December 31, 2011. This is attributable to the inclusion of GMOL in Provincial EDL such as the provinces of Henan and Shandong and the City of Chongqing. The contribution from our distribution business through TMT amounted to $4.6 million at 13% gross margin.

    Gross Margin for the quarter ended December 31, 2012 was 38.7% as compared to 33.4% for the quarter ended December 31, 2011. Our gross margin improved mainly as a result of a greater mix of higher margin products sold during the period supported by a stabilization of generic pricing pressure. While a trend of continuous margin improvement has not yet been affirmed the present sales data supports a flattening and slightly positive trend in our gross margins.

    Operating Expenses were $4.2 million for the quarter ended December 31, 2012, as compared to $4.0 million for the quarter ended December 31, 2011. The increase in operating expenses was mainly associated with an increase in sales and marketing costs.

    Net Income was $1.8 million at a net margin of 10.2% for the quarter ended December 31, 2012, as compared to net income of $1.7 million with net margin of 9.5% for the quarter ended December 31, 2011. This was mainly due to improvements in our gross margins.

    Diluted earnings per share for the quarter ended December 31, 2012 were $0.06 based on 29.3 million shares compared with the earnings of $0.06 per diluted share for the quarter ended December 31, 2011, based on 29.4 million shares.

    Balance Sheet and Cash FlowAs of December 31, 2012, we had working capital totaling $34.1 million, including cash and cash equivalents of $25.4 million. Net cash used in operating activities was $(0.7) million for the six months ended December 31, 2012 as compared to net cash generated from operating activities as $7.9 million for the six months ended December 31, 2011. The net decrease in operating cash flow was predominately the result of: 1) the payment of trade notes payable of $(4.7) million that was due during the six months ended December 31, 2012; 2) an increase of inventory of $(1.1) million, and 3) an increase of accounts receivables of $0.8 million and advance from customer of $0.6 million. We believe that TPI is adequately funded to meet all of our working capital and capital expenditure needs for fiscal year 2013.

    Business Development & OutlookR&D for additional indications of flagship product Gingko Mihuan (GMOL)

    Our flagship product GMOL (SFDA certification number: H20013079; patent number: 20061007800225) contributes approximately 37% to our total revenue. Clinical application and information gathered from our physicians showed that in addition to our approved indication for GMOL: cardiovascular disorders, coronary heart disease and cerebral ischemic attack including strokes, off-label use of GMOL have been indicated in hepatic diseases and ophthalmological diseases. The validity of these observations is currently being investigated.

    Jiangchuan Macrolide Project (JCM)

    TPI has completed the 240-ton JCM facility for the R&D, manufacturing and sale of API and chemical intermediates of macrolide antibiotics. In January 2012, JCM was approved for its GMP certification designated as "CHUAN M0799," which is valid for the period of December 31, 2011 until December 31, 2015. After an initial three month period of efficiency improvement and calibration for large scale production, JCM has started producing macrolide API for TPI's production of Azithromycin Dispersible Tablets (SFDA No: H20074145) since July 2012. Currently the monthly production capacity of JCM is 10 tons of Azithromycin macrolide API.

    Tianyin Medicine Trading Distribution Business (TMT)

    TMT is established to distribute products manufactured by both TPI and other pharmaceutical companies to fuel our expanding sales network as well as to provide synergy to our existing organic product portfolio. TMT has been distributing mainly TPI's own products since its inception in 2009. Since 2010, TPI has signed and later extended distribution contracts with Jiangsu Lianshui Pharmaceutical ("Lianshui") to distribute Lianshui-branded generic injection products including cough suppressant, antibiotics, anti-inflammatory medicines and other healthcare indications. On average, TMT distribution revenue contributed approximately $3-5 million sales per quarter to our total revenue.

    Pre-extraction and formulation plant development at Qionglai Facility (QLF)

    In preparation for the new Good Manufacturing Practice (GMP) standards stipulated by the PRC government in early 2011, TPI initiated the process of optimizing the manufacturing facilities and production lines in compliance with the new GMP standards by 2013. Concurrently, the city of Chengdu has re-designated various industrial parks for particular industries such as automobile, biotechnologies, pharmaceuticals and chemical engineering. As a consequence, TPI's current manufacturing facility at the Longquan district, east of Chengdu, which is designated for use by the automotive industry, is scheduled to be relocated to Qionglai city, south of Chengdu, which is designated for use by the pharmaceutical industry. The Qionglai facility (QLF) is approximately 18 miles from the Company's recently completed JCM facility. The proposed relocation project also includes our TCM pre-extraction plant, which is located near the center of city of Chengdu, a rapidly expanding residential area.

    The QLF is estimated to be 80 mu or approximately 13 acres. Both pre-extraction plant and the formulation plant are to be relocated. The combined QLF plant, designed and constructed according to the latest GMP standards, is expected to relieve the current capacity saturation at TPI's facilities. The re-location and construction cost is estimated at $25 million for Phase I which is scheduled to be completed in the first half of 2013 calendar year,  will expand the current capacity by 30%. In order to facilitate a favorable tax treatment for QLF, Chengdu Tianyin entered into a Share Transfer Agreement (the "Agreement") with the two shareholders of Sichuan Hengshuo Pharmaceutical Co., Ltd ("Sichuan Hengshuo" or "HSP") to acquire 100% ownership of the latter, a PRC pharmaceutical trading company, for a total consideration of approximately $0.2 million (RMB 1.3 million). The share transfer was closed on November 30, 2012. As of December 31, 2012, results of HSP are consolidated into the consolidated financial statements presented herein. Currently HSP has not yet been in operation since the closing.

    Fiscal 2013 GuidanceWe are assuming that continued pricing pressures in our marketplace shall remain for the second half of fiscal 2013 amid ongoing healthcare reform in China which may continue to put pressure on our revenue growth for the year. Yet we expect that JCM and TMT distribution business may help TPI to offset these external pressures to deliver 2013 revenue growth of approximately 10% to 15%. We reiterate our fiscal 2013 revenue projection of approximately $75 to $80 million along with a net margin of approximately 10%.

    We believe the following factors will influence the growth perspectives of TPI: 1) Market expansion and revenue growth of TPI's core product portfolio led by flagship product GMOL, Azithromycin and other major products; 2) Ramp up of JCM revenue in the fiscal year 2013; 3) The gradual stabilization of generic sales following the progressive pricing restrictions as a result of the ongoing healthcare reform; 4) Steady TMT distribution revenue contribution; and 5) QLF relocation and smooth transition of production capacity.Management will continue to evaluate the Company's business outlook and communicate any changes on a quarterly basis or as when appropriate.

    Conference CallSenior management of TPI will host its earnings conference call for the second quarter of fiscal year 2013 ending December 31, 2012 to be held at 8:30 a.m. ET on Thursday, February 14, 2013.

    Interested parties may access the call by dialing toll free: 1-877-941-2068; international: 1-480-629-9712

    The conference ID is 4594892. It is advisable to dial in approximately 5 minutes prior to the start of the call.

    A replay will be available by calling toll free: 1-877-870-5176; international: 1-858-384-5517 from: 02/14/13 @ 11:30 am ET to: 02/28/13 @ 11:59 pm ET. Replay Pin Number: 4594892

    This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link:

    About TPI

    Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications.

    For more information about TPI, please visit: or write to:

    Safe Harbor Statement

    The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

     Tianyin Pharmaceutical Co., Inc.Consolidated Balance SheetsDecember 31,
    2012June 30,
    2012Assets(Unaudited)Current assets:Cash and cash equivalents$


    35,152,295Restricted cash-3,534,550Accounts receivable, net of allowance for doubtful accounts of $114,006and $113,862 at December 31, 2012 and June 30,
    2012, respectively10,500,19911,272,367Inventory6,970,4785,863,013Advance payments -642,075Other current assets451,358436,664Total current assets43,361,68856,900,964Property and equipment, net32,848,63026,458,349Intangibles, net20,584,58920,958,226Advance payments – construction and equipment5,300,580-Goodwill206,310-Total assets$102,301,797$104,317,539LiabilitiesCurrent liabilities:Accounts payable and accrued expenses$


    1,586,151Accounts payable – construction related411,938740,832Short-term bank loans6,030,6006,023,000Trade notes payable-4,675,750Income tax payable667,583804,595Other taxes payable468,545500,782Other current liabilities434,017466,982Total current liabilities9,281,33814,798,092Total liabilities9,281,33814,798,092EquityStockholders' equity:Common stock, $0.001 par value, 
    50,000,000 shares authorized, 29,332,791
      shares issued and outstanding at December
      31, 2012 and June 30, 2012, respectively
    29,44629,446Additional paid-in capital30,122,63230,104,902Treasury stock(135,925)(135,925)Statutory reserve6,120,1436,120,143Retained earnings48,427,89645,022,329Accumulated other comprehensive income8,214,4908,100,526Total stockholders' equity92,778,68289,241,421Noncontrolling interest241,777278,026Total equity93,020,45989,519,447Total liabilities and equity$102,301,797$104,317,539 Tianyin Pharmaceutical Co., Inc.Consolidated Statements of Operations(Unaudited)For the Three Months EndedFor the Six Months EndedDecember 31,December 31,2012201120122011Sales$17,603,298$18,236,701$33,574,995$35,765,279Cost of sales10,799,51612,148,39920,527,50923,823,928Gross profit6,803,7826,088,30213,047,48611,941,351Operating expenses:Selling expenses2,885,0872,801,6305,646,5255,278,956General and administrative expenses1,097,8541,022,0392,219,3872,041,161Research and development222,423210,784438,353421,499Total operating expenses4,205,3644,034,4538,304,2657,741,616Income from operations2,598,4182,053,8494,743,2214,199,735Other income (expenses):Interest income31,84243,24699,44478,207Interest expense(113,468)(82,930)(221,872)(132,775)Gain on disposal of fixed assets-229,110-229,110Other expenses-(5,115)-(9,833)Total other income (expenses)(81,626)184,311(122,428)164,709Income before provision for income tax2,516,7922,238,1604,620,7934,364,444Provision for income tax668,762556,5901,251,8101,175,657Net income1,848,0301,681,5703,368,9833,188,787Less: Net loss attributable tononcontrolling interest(15,920)(56,035)(36,584)(74,058)

    Net income
      attributable to
    Tianyin Pharmaceutical
      Co., Inc.













    3,262,845Basic earnings per share$0.06$0.06$0.12$0.11Diluted earnings per share$0.06$0.06$0.12$0.11Weighted average number of commonshares outstandingBasic29,332,79129,396,27629,332,79129,396,276Diluted29,332,79129,396,27629,332,79129,396,276 Tianyin Pharmaceutical Co., Inc.Consolidated Statements of Comprehensive Income(Unaudited)For the Three Months EndedFor the Six Months EndedDecember 31,December 31,2012201120122011Net income$1,848,030$1,681,570$3,368,983$3,188,787Other comprehensive incomeForeign currency translation adjustment226,799567,535114,2991,515,042Comprehensive income2,074,8292,249,1053,483,2824,703,829Less: comprehensive income (loss)attributable to 
      interest(15,225)(52,025)(36,249)185,379Comprehensive income attributable toTianyin Pharmaceutical Co., Inc.$2,090,054$2,301,130$3,519,531$4,518,450 Tianyin Pharmaceutical Co., Inc.Consolidated Statements of Cash Flows(Unaudited)For the Six Months EndedDecember 31,20122011Cash flows from operating activities:Net Income$


    3,188,787Adjustments to reconcile net income to net cashprovided by (used in) operating activities:Depreciation and amortization1,171,649518,131Gain on disposal of fixed assets-(229,110)Share-based payments17,730-Provision for bad debts-43,726Changes in current assets and current liabilities:Accounts receivable786,04546,185Inventory(1,099,581)908,557Advance payments642,6021,662,080Other current assets(14,137)(154,593)Accounts payable and accrued expenses(319,349)608,143Accounts payable – construction related(329,684)(579,391)Trade notes payable(4,679,585)2,665,260Income tax payable(137,967)(345,177)Other taxes payable(32,854)(386,642)Other current liabilities(33,539)(31,265)Total adjustments(4,028,670)4,725,904Net cash provided by(used in)
    operating activities(659,687)7,914,691Cash flows from investing activities:Additions to property and equipment(1,002,716)(2,836)Proceeds from disposal of fixed assets-377,164Advance payments – construction and equipment(5,298,242)-Additions of construction in progress(6,123,118)(136,400)Acquisition of subsidiary–Hengshuo (HSP)(206,219)-Additions to intangible assets – approved drugs-(768,222)Additions to intangible assets – land use right-(1,822,780)Net cash used in investing activities(12,630,295)(2,353,074)Cash flows from financing activities:Restricted cash3,537,449(3,104,244)Proceeds from short-term bank loans-1,567,800Net cash provided by(used in) financing activities3,537,449(1,536,444)Effect of foreign currency translation on cash39,8911,158,325Net increase(decrease) in cash and cash equivalents(9,712,642)5,183,498Cash and cash equivalents – beginning35,152,29531,724,906Cash and cash equivalents – ending$25,439,653$36,908,404Supplemental disclosures of cash activitiesCash paid for interest$


    132,775Cash paid for income taxes$


    1,560,653For more information, please contact:
    Investors Contact:
    Tel: +86-28-8551-6696 (Chengdu, China)
    +86-134-36-550011 (China)

    23rd Floor Unionsun Yangkuo Plaza
    No. 2, Block 3, South Renmin Road
    Chengdu, 610041

    SOURCE Tianyin Pharmaceutical Co., Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
    2. Hanger Reports $0.62 Diluted EPS for the Fourth Quarter 2012
    3. Hospira Reports Fourth-Quarter and Full-Year 2012 Results
    4. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
    5. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
    6. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
    7. Allied Healthcare Products Reports Second Quarter Loss
    8. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at
    9. Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at
    10. Misonix Reports Financial Results for First Half of Fiscal 2013
    11. CareFusion Reports First Half Fiscal 2013 Results
    Post Your Comments:
    (Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
    (Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
    (Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
    (Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
    (Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
    (Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
    (Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
    Breaking Medicine News(10 mins):